- NEWS AND VIEWS
Multiple sclerosis enters a grey area
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 566, 465-466 (2019)
doi: https://doi.org/10.1038/d41586-019-00563-6
References
The International Multiple Sclerosis Genetics Consortium. Nature 476, 214–219 (2011).
Lodygin, D. et al. Nature 566, 503–508 (2019).
Stern, J. N. et al. Sci. Transl. Med. 6, 248ra107248ra107 (2014).
Dendrou, C. A., Fugger, L. & Friese, M. A. Nature Rev. Immunol. 15, 545–558 (2015).
Ota, K. et al. Nature 346, 183–187 (1990).
Cao, Y. et al. Sci. Transl. Med. 7, 287ra74 (2015).
Jelcic, I. et al. Cell 175, 85–100 (2018).
Lucchinetti, C. F. et al. N. Engl. J. Med. 365, 2188–2197 (2011).
Calabrese, M. et al. Brain 135, 2952–2961 (2012).
Brown, J. W. L. et al. J. Am. Med. Assoc. 321, 175–187 (2019).
Mor, F., Quintana, F., Mimran, A. & Cohen, I. R. J. Immunol. 170, 628–634 (2003).
Sulzer, D. et al. Nature 546, 656–661 (2017).
Vargas, K. J. et al. J. Neurosci. 34, 9364–9376 (2014).
Competing Interests
D.A.H. has received funding from Bristol-Myers Squibb, Novartis and Genentech. D.A.H. has been a consultant for Compass Therapeutics, EMD Serono, Novartis Pharmaceuticals, Sanofi Genzyme and Versant Venture, Genentech and Proclara Bioscience.